FIELD: organic chemistry; pharmacology.
SUBSTANCE: group of inventions relates to the field of organic chemistry and pharmacology, namely to compounds having inhibitory activity of cyclin-dependent kinases (hereinafter – CDKs). A compound of the formula (IX) or its pharmaceutically acceptable salt is disclosed, where: R1 is H, F, Cl, CN, C1-C2alkyl, or C1-C2fluoroalkyl, where each specified C1-C2alkyl and C1-C2fluoroalkyl is optionally substituted with R20; R2 is H, C1-C5alkyl, C1-C5fluoroalkyl, C3-C8cycloalkyl, oxetan-3-yl, azetidine-3-yl, or oxolan-3-yl, where each specified C1-C5alkyl and C1-C5fluoroalkyl is optionally substituted with R20, and each specified C3-C8cycloalkyl and oxetan-3-yl, azetidine-3-yl, or oxolan-3-yl is optionally substituted with R21; R4 is H, C1-C4alkyl, C1-C4fluoroalkyl, C1-C4alkoxy, or C1-C4fluoroalkoxy, where each specified C1-C4alkyl, C1-C4fluoroalkyl, C1-C4alkoxy, and C1-C4fluoroalkoxy is optionally substituted with R20; R6 is H, F, Cl, CN, CH3, CH2F, CHF2, or CF3; R7 and R8 are independently H, F, Cl, CN, C1-C2alkyl, C1-C2fluoroalkyl, C1-C2alkoxy, or C1-C2fluoroalkoxy, where each specified C1-C2alkyl, C1-C2fluoroalkyl, C1-C2alkoxy, and C1-C2fluoroalkoxy is optionally substituted with R20; R9 is H, OH, or N(CH3)2; each R10 is independently F, CN, C1-C2alkyl, or C1-C2fluoroalkyl, where each specified C1-C2alkyl and C1-C2fluoroalkyl is optionally substituted with R20; R11 is H, C1-C4alkyl, C1-C4fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17, or CONR18R19; R14 is C1-C4alkyl or C1-C4fluoroalkyl; each R15 and R16 is independently H or CH3; R17 is C1-C4alkyl or C1-C4fluoroalkyl, where each specified C1-C4alkyl and C1-C4fluoroalkyl is optionally substituted with R20; each R18 and R19 is independently H, C1-C4alkyl, or C1-C4fluoroalkyl, where each specified C1-C4alkyl and C1-C4fluoroalkyl is optionally substituted with R20; each R20 is independently OH, C1-C2alkoxy, C1-C2fluoroalkoxy, CN, or NR22R23; each R21 is independently F, OH, CN, NR22R23, C1-C4alkyl, C1-C4fluoroalkyl, C1-C4alkoxy, or C1-C4fluoroalkoxy, where each specified C1-C4alkyl, C1-C4fluoroalkyl, C1-C4alkoxy, and C1-C4fluoroalkoxy is optionally additionally substituted with OH, NH2, NHCH3, or N(CH3)2; each R22 and R23 is independently H, C1-C2alkyl, or C1-C2fluoroalkyl, or R22 and R23 can be taken together with a nitrogen atom, to which they are attached, to form an azetidinyl ring, which is optionally substituted with F or OH; and n is 0, 1, 2, 3, or 4. In addition, a pharmaceutical composition inhibiting activity of cyclin-dependent kinases (CDKs) is described, as well as a cancer treatment method including the administration of therapeutically effective amount of the specified compound to an object.
EFFECT: group of inventions provides effective cancer treatment.
15 cl, 6 tbl, 150 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF 2-AMINOPYRIDINE OR 2-AMINOPYRIMIDINE AS CYCLIN-DEPENDENT KINASE INHIBITORS | 2019 |
|
RU2762557C1 |
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
| β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV | 2016 |
|
RU2764767C2 |
| 5-FLUOROPYRIMIDINE DERIVATIVES AS FUNGICIDES | 2009 |
|
RU2522430C2 |
| CETP INHIBITORS | 2006 |
|
RU2513107C2 |
| PYRIDINONE AND PYRIDAZINONE DERIVATIVES | 2012 |
|
RU2632915C2 |
| BRIDGED N-CYCLYC SULPHONAMIDO-INHIBITORS OF GAMMA-SECRETASE | 2006 |
|
RU2422443C2 |
| AMIDES OF QUINOLINE AND QUINAZOLINE, USEFUL AS A SODIUM CHANNEL MODULATORS | 2014 |
|
RU2683788C2 |
| DELAYED-RELEASE DELIVERY SYSTEMS CONTAINING TRACELESS LINKERS | 2018 |
|
RU2772690C2 |
| APELIN RECEPTOR AGONISTS (APJ) AND USE THEREOF | 2015 |
|
RU2705800C2 |
